EURAZEO ACQUIRES THE REMAINING CAPITAL OF KURMA PARTNERS, AN ASSET MANAGEMENT COMPANY SPECIALISING IN MEDICAL INNOVATION AND BIOTECHNOLOGY

EURAZEO ACQUIRES THE REMAINING CAPITAL OF KURMA PARTNERS, AN ASSET MANAGEMENT COMPANY SPECIALISING

IN MEDICAL INNOVATION AND BIOTECHNOLOGY

Paris, April 30^th, 2025 

Eurazeo announces the acquisition of the remaining shares in Kurma Partners, a French asset management company specialising in biotechnology and medical innovation. This transaction follows Eurazeo’s majority stake acquisition (70.6%) in 2021, in line with the agreements signed at the time.

With nearly €600 million in assets under management, Kurma Partners has established itself since 2009 as a key player in the European healthcare sector, supporting the most promising companies in the field. The recent first closing of Kurma Biofund IV (€140 million – SFDR article 8) illustrates its leading role in financing innovative therapeutic solutions.

Recent trade exits (Amolyt Pharma, Emergence Therapeutics, Still Technologies) highlight its ability to create value and support the emergence of European leaders.

Since 2021, Eurazeo, a long-standing investor in Kurma, has already committed nearly €100 million to its funds and has provided operational support as well as access to its international platform. The Group will continue to actively support Kurma Partners’ growth.

This increased stake forms part of Eurazeo’s broader commitment to the healthcare sector, through both generalist and specialist funds. By the end of 2024, the Group’s assets under management dedicated to healthcare investments total €3 billion.

Christophe Bavière and William Kadouch-Chassaing, Co-CEOs of Eurazeo, declared:

“Healthcare innovation is a strategic sector for Eurazeo. This acquisition strengthens our platform in early-stage investment, while preserving Kurma

Partners’ entrepreneurial DNA and operational independence.“ 

Rémi Droller, Managing Partner at Kurma Partners, added:

“The strength of the Eurazeo–Kurma platform reinforces our European ambition and amplifies our impact in healthcare. Together, we are building a leading player in medical innovation across Europe.“  

EURAZEO 

66, rue Pierre Charron – 75008 Paris www.eurazeo.com

 1 / 2

ABOUT EURAZEO

•       Eurazeo is a leading European investment group with €36.1 billion in diversified assets under management, including €26.2 billion on behalf of institutional and retail clients through its private equity, private debt, real estate and infrastructure strategies. The Group supports more than 600 mid-market companies, leveraging the commitment of its 400-strong workforce, its in-depth sector expertise, its privileged access to global markets through 13 offices across Europe, Asia and the United States, and its responsible approach to value creation based on growth. The company's institutional and family shareholding structure, and its solid financial structure, ensure its long-term viability. 

•       Eurazeo has offices in Paris, New York, London, Frankfurt, Berlin, Milan, Madrid, Luxembourg, Shanghai, Seoul, Singapore, Tokyo and São Paulo.

•       Eurazeo is listed on Euronext Paris. 

•       ISIN: FR000121121 - Bloomberg: RF FP - Reuters: EURA.PA.

EURAZEO CONTACT                                                            PRESS CONTACT 

Coralie Savin                                                                                         Mael Evin (France)

GROUP CHIEF COMMUNICATIONS OFFICER                            HAVAS

csavin@eurazeo.com                 mael.evin@havas.com +33 (0)6 86 89 57 48       +33 (0)6 44 12 14 91

Pierre Bernardin                                                                                 David Sturken (UK)

MANAGING DIRECTOR – HEAD OF       H/ADVISORS MAITLAND INVESTOR RELATIONS              david.sturken@h-advisors.global ir@eurazeo.com         +44 (0) 7990 595 913

+33 (0)1 44 15 01 11                                                                             

EURAZEO 

66, rue Pierre Charron – 75008 Paris www.eurazeo.com

 2 / 2